| Literature DB >> 33073685 |
Neha Joshi1, Crystal Nguyen1, Anastasia Ivanova1.
Abstract
We consider the problem of estimating the best subgroup and testing for treatment effect in a clinical trial. We define the best subgroup as the subgroup that maximizes a utility function that reflects the trade-off between the subgroup size and the treatment effect. For moderate effect sizes and sample sizes, simpler methods for subgroup estimation worked better than more complex tree-based regression approaches. We propose a three-stage design with a weighted inverse normal combination test to test the hypothesis of no treatment effect across the three stages.Entities:
Keywords: Adaptive enrichment; predictive biomarker; subgroup estimation
Mesh:
Year: 2020 PMID: 33073685 PMCID: PMC7954857 DOI: 10.1080/10543406.2020.1832109
Source DB: PubMed Journal: J Biopharm Stat ISSN: 1054-3406 Impact factor: 1.051